Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KRAS G12V Mutant Peptide-HLA-A*11:01 Complex (KRAS G12V-HLA-A*11:01)
- Target
- KRAS G12V-HLA-A*11:01
- Molecular classification
- MHC Class I complex, Neoantigen complex, Peptide-HLA complex
01
Overview
The KRAS G12V Mutant Peptide-HLA-A*11:01 Complex is a molecular complex formed by the binding of a 9-mer peptide derived from the oncogenic KRAS protein (with a glycine-to-valine substitution at position 12, sequence: VVGAVGVGK) to the HLA-A*11:01 molecule. This complex is presented on the surface of cells and recognized by T cell receptors (TCRs), making it a promising target for T cell-based cancer immunotherapies against tumors harboring the KRAS G12V mutation. The structure reveals how the mutant valine residue at position 12 is accommodated within the binding groove of HLA-A*11:01.
- Other names
- KRAS G12V/HLA-A*11:01HLA-A*11:01-KRAS G12V complexVVGAVGVGK-HLA-A*11:01
02
Mechanism of action
Targeting of cancer cells presenting the KRAS G12V-HLA-A*11:01 complex via T cell receptor (TCR) engagement
03
Biological functions
Antigen presentationT cell activationImmune recognitionTumor immunosurveillance
04
Disease associations
CancerPancreatic cancer
05
Safety considerations
On-target, off-tumor toxicityCytokine release syndromeImmune-related adverse events
06
Biomarkers
KRAS G12V mutation statusHLA-A*11:01 allele expressionTCR recognition of the complex
Beyond the preview
Go deeper on KRAS G12V Mutant Peptide-HLA-A*11:01 Complex (KRAS G12V-HLA-A*11:01).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS G12V Mutant Peptide-HLA-A*11:01 Complex (KRAS G12V-HLA-A*11:01).